/ORGS
ORGS Stock - Orgenesis Inc.
Healthcare|BiotechnologyOTC
$0.75+200.00%
+$0.50 (+200.00%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ORGS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.74 – $0.76
TARGET (TP)$0.86
STOP LOSS$0.69
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.17
52W High$5.89
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $530,000 | $36.02M | $35.50M | $7.65M | $33.26M |
| Gross Profit | $-5,725,000 | $15.59M | $7.34M | $-23,447,000 | $15.14M |
| Gross Margin | -1080.2% | 43.3% | 20.7% | -306.4% | 45.5% |
| Operating Income | $-53,636,000 | $-7,541,000 | $-16,800,000 | $-95,781,000 | $-24,604,000 |
| Net Income | $-55,361,000 | $-14,889,000 | $-18,059,000 | $-95,808,000 | $-26,041,000 |
| Net Margin | -10445.5% | -41.3% | -50.9% | -1252.1% | -78.3% |
| EPS | $-1.91 | $-0.59 | $-0.74 | $-4.46 | $-1.64 |
Company Overview
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ORGSBeat Rate
25%
Last 12 quarters
Avg Surprise
-637.8%
EPS vs Estimate
Beats / Misses
3/9
Last 12 quarters
Latest EPS
$-1.93
Q4 2024
EPS Surprise History
Q4 22
-150.0%
$-0.50vs$-0.20
Q2 23
-3500.0%
$-1.70vs$0.05
Q2 24
No data
Q2 24
No data
Q2 24
-107.1%
$-0.13vs$1.80
Q2 24
-825.0%
$-2.90vs$0.40
Q3 24
-264.3%
$-2.30vs$1.40
Q4 24
-213.5%
$-1.93vs$1.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 11, 2025 | — | — | — | — |
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 15, 2025 | — | — | — | — |
Q2 2025 | Apr 22, 2025 | — | — | — | — |
Q4 2024 | Nov 13, 2024 | $1.70 | $-1.93 | -213.5% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $1.40 | $-2.30 | -264.3% | ✗ MISS |
Q2 2024 | May 21, 2024 | $0.40 | $-2.90 | -825.0% | ✗ MISS |
Q2 2024 | Apr 15, 2024 | $1.80 | $-0.13 | -107.1% | ✗ MISS |
Q2 2024 | Apr 15, 2024 | — | $-0.74 | — | — |
Q2 2024 | Apr 15, 2024 | — | $-0.90 | — | — |
Q1 2024 | Mar 5, 2024 | $0.18 | — | — | — |
Q2 2023 | May 10, 2023 | $0.05 | $-1.70 | -3500.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.20 | $-0.50 | -150.0% | ✗ MISS |
Q3 2022 | Aug 16, 2022 | $-0.20 | $-2.20 | -1000.0% | ✗ MISS |
Q2 2022 | May 23, 2022 | $-0.40 | $-1.60 | -300.0% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.06 | $-2.00 | -3233.3% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.35 | $4.20 | +1300.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.23 | $1.10 | +578.3% | ✓ BEAT |
Q2 2021 | May 7, 2021 | $-0.26 | $-0.10 | +61.5% | ✓ BEAT |
Q1 2021 | Mar 9, 2021 | — | $-2.34 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ORGS
What is ORGS's current stock price?
Orgenesis Inc. (ORGS) is currently trading at $0.75 per share. The stock has moved +200.00% today.
What is the analyst price target for ORGS?
No analyst price targets are currently available for this stock.
What sector is Orgenesis Inc. in?
Orgenesis Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ORGS's market cap?
Orgenesis Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ORGS pay dividends?
No, Orgenesis Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBPTH
Bio-Path Holdings, Inc.
$0.07
Mkt Cap: $0.0B
EMMA
Emmaus Life Sciences, Inc.
$0.01
Mkt Cap: $0.0B
HXBM
Helix BioMedix, Inc.
$2.70
Mkt Cap: $0.0B
IDCN
Indocan Resources Inc.
$0.00
Mkt Cap: $0.0B
NGMC
Next Generation Management Corp.
$0.00
Mkt Cap: $0.0B
NTRR
Neutra Corp.
$0.00
Mkt Cap: $0.0B
PAIOF
Paion AG
$0.01
Mkt Cap: $0.0B
SQZB
SQZ Biotechnologies Company
$0.02
Mkt Cap: $0.0B
UNBX
Unity Biotechnology, Inc.
$0.06
Mkt Cap: $0.0B
VPRO
Viropro Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ORGS for comparison